BeboBFJr, et al. The refined pathways to cures research roadmap for multiple sclerosis cures. Mult Scler J2024; 30(10): 1242–1251.
2.
BeboBFJrAllegrettaMLandsmanD, et al. Pathways to cures for multiple sclerosis: A research roadmap. Mult Scler J2022; 28(3): 331–345.
3.
BeboBFJrCoetzeeTGrayE, et al. The first global landscape analysis of multiple sclerosis research funding. Mult Scler J, 2024; 30(10): 1366–1372.
4.
FoxRJThompsonABakerD, et al. Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Mult Scler J2012; 18(11): 1534–1540.
5.
The Lancet Neurology. Patient-reported outcomes in the spotlight. Lancet Neurol2019; 18(11): 981.
6.
YamoutBIViswanathanSLaurson-DoubeJ, et al. Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation. Mult Scler J2024; 30(1): 3–6.
7.
KalkmanSvan DeldenJBanerjeeA, et al. Patients’ and public views and attitudes towards the sharing of health data for research: a narrative review of the empirical evidence. J Med Ethics2022; 48(1): 3–13.
8.
MowryEMBermelRAWilliamsJR, et al. Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Front Neurol2020; 11: 632.
9.
MateenFJ. Multiple sclerosis in resource-limited settings: Research opportunities in an unequal world. Neurology2019; 93(4): 176–180.
